THCV to Alleviate Cancer Therapy Side-effects
A remarkable invention has surfaced this week disclosed in issued US patent 10,688,191 for a chemically linked cannabinoid and chemotherapy agent. As the chemotherapy agent breaches the blood-brain barrier, the linked cannabinoid is able to act on the endocannabinoid receptors to alleviate some of the side effects of the chemotherapy agent.
Patent ‚Äò191 specifically mentions the use of tetrahydrocannabivarin (THCV) and Carmustine as the cannabinoid and chemotherapy agent, respectively. THCV is a homologue molecule of THC and produces different side effects from THC. Cannabis site Leafly states that the common effects of THCV include appetite suppressant, stimulating bone growth as well as possibly helping with Alzheimer’s disease, diabetes, and reducing panic attacks.
HR BIOMED LLC, a Goshen, OH based company, is the assignee for patent ‚Äò191 and appears to be operating in stealth mode at the moment. Check out Magic Number’s Cannabis Patent Forecast® to stay up to date with the cannabis industry’s vast set of intellectual property.
Related Posts
Cannabis Popularity Soars Along With Tests To Detect It
The Duquenois Levine Test is used in the field by law enforcement officers to test for THC presence in a suspected sample. The problem with…
Hound Labs, Cannabix and Vox Heat Up the Marijuana Breathalyzer Market
At the start of April 2021, Patent Forecast® released an insight going over some of the big name competitors getting their foot in the door…
Driving While High? Cannabis Sobriety Testing Heats Up
What’s the future of cannabis innovation? We see things before they happen using our Patent Forecast®. One of those is the development of…